

NCT01944800 Raw comparison:

Summary:
CHIA has 23 criteria while your personal folder has 26 criteria
Total found criteria: 22/23
Total not Found: 1/23
Total Extra: 3
This trial is INVALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ intolerance of or allergy to ticagrelor or         │ intolerance of or allergy to ticagrelor or         │
│ prasugrel                                          │ prasugrel                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ history of any stroke transient ischemic attack or │ history of any stroke transient ischemic attack or │
│ intracranial bleeding                              │ intracranial bleeding                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ known intracranial neoplasm intracranial           │ known intracranial neoplasm intracranial           │
│ arteriovenous malformation or intracranial         │ arteriovenous malformation or intracranial         │
│ aneurysm                                           │ aneurysm                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ active bleeding clinical findings that in the      │ active bleeding clinical findings that in the      │
│ judgement of the investigator are associated with  │ judgement of the investigator are associated with  │
│ an increased risk of bleeding                      │ an increased risk of bleeding                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ fibrin-specific fibrinolytic therapy less than 24  │ fibrin-specific fibrinolytic therapy less than 24  │
│ h before randomization non-fibrin-specific         │ h before randomization non-fibrin-specific         │
│ fibrinolytic therapy less than 48 h before         │ fibrinolytic therapy less than 48 h before         │
│ randomization                                      │ randomization                                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ known platelet count < 100 000/µL at the time of   │ known platelet count \< 100 000/μL at the time of  │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ known anemia (hemoglobin <10 g/dL) at the time of  │ known anemia (hemoglobin \<10 g/dL) at the time of │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ oral anticoagulation that cannot be safely         │ oral anticoagulation that cannot be safely         │
│ discontinued for the duration of the study         │ discontinued for the duration of the study         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ INR known to be greater than 1 5 at the time of    │ INR known to be greater than 1 5 at the time of    │
│ screening                                          │ screening                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ chronic renal insufficiency requiring dialysis     │ chronic renal insufficiency requiring dialysis     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ moderate or severe hepatic dysfunction (Child Pugh │ moderate or severe hepatic dysfunction (Child Pugh │
│ B or C)                                            │ B or C)                                            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ increased risk of bradycardia events (Sick Sinus   │ increased risk of bradycardia events (Sick Sinus   │
│ AV block grade II or III bradycardia-induced       │ AV block grade II or III bradycardia-induced       │
│ syncope)                                           │ syncope)                                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ index event is an acute complication (< 30 days)   │ index event is an acute complication (\< 30 days)  │
│ of PCI                                             │ of PCI                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ concomitant medical illness that in the opinion of │ concomitant medical illness that in the opinion of │
│ the investigator is associated with a life         │ the investigator is associated with a life         │
│ expectancy < 1 year                                │ expectancy \< 1 year                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ concomitant oral or i v therapy with strong CYP3A  │ concomitant oral or i v therapy with strong CYP3A  │
│ Inhibitors (e g ketoconazole itraconazole          │ Inhibitors (e g ketoconazole itraconazole          │
│ voriconazole telithromycin clarithromycin          │ voriconazole telithromycin clarithromycin          │
│ nefazodone ritonavir saquinavir nelfinavir         │ nefazodone ritonavir saquinavir nelfinavir         │
│ indinavir atazanavir grapefruit juice > 1 L/d)     │ indinavir atazanavir grapefruit juice \> 1 L/d)    │
│ CYP3A substrates with narrow therapeutic indices   │ CYP3A substrates with narrow therapeutic indices   │
│ (e g cyclosporine quinidine) or strong CYP3A       │ (e g cyclosporine quinidine) or strong CYP3A       │
│ inducers (e g rifampin/rifampicin phenytoin        │ inducers (e g rifampin/rifampicin phenytoin        │
│ carbamazepine dexamethason phenobarbital ) that    │ carbamazepine dexamethason phenobarbital ) that    │
│ cannot be safely discontinued                      │ cannot be safely discontinued                      │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ =1 doses of ticagrelor or prasugrel within 5 days  │ ≥1 doses of ticagrelor or prasugrel within 5 days  │
│ before randomisation                               │ before randomisation                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ no written informed consent                        │ no written informed consent                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ participation in another investigational drug      │ participation in another investigational drug      │
│ study                                              │ study                                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ previous enrolment in this study                   │ previous enrolment in this study                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ for women of childbearing potential no negative    │ for women of childbearing potential no negative    │
│ pregnancy test and no agree to use reliable method │ pregnancy test and no agree to use reliable method │
│ of birth control during the study                  │ of birth control during the study                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnancy giving birth within the last 90 days or  │ Pregnancy giving birth within the last 90 days or  │
│ lactation                                          │ lactation                                          │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ inability to cooperate with protocol requirements  │ inability to cooperate with protocol requirements  │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



╒═══════════════════════════════════════╕
│ CHIA Criteria Not Found in Personal   │
╞═══════════════════════════════════════╡
│ NA                                    │
╘═══════════════════════════════════════╛



╒═════════════════════════════════════════════════════════════════════════════════════════════════════╕
│ Extra Personal Criteria                                                                             │
╞═════════════════════════════════════════════════════════════════════════════════════════════════════╡
│ Major                                                                                               │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Hospitalization for an acute coronary syndrome (ST-segment elevation myocardial infarction non-ST-  │
│ segment elevation myocardial infarction or unstable angina pectoris) with planned invasive strategy │
├─────────────────────────────────────────────────────────────────────────────────────────────────────┤
│ Must have minimum age of 18 Years                                                                   │
╘═════════════════════════════════════════════════════════════════════════════════════════════════════╛